The Economic Burden of Opioid-Related Poisoning in the United States

Pain Medicine (United States)

Volumn 14, Issue 10, 2013, Pages 1534-1547

  Inocencio, Timothy J ^a   Carroll, Norman V ^b   Read, Edward J ^b   Holdford, David A ^b  

^a Avalere Health   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Costs; Heroin; Opiate; Opioid; Overdose; Poisoning

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; DIAMORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; OPIATE; OPIATE DERIVATIVE; OXYCODONE; PSYCHEDELIC AGENT;

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG INTOXICATION; ECONOMIC ASPECT; EMERGENCY WARD; HEALTH CARE COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OPIOID POISONING; PATIENT TRANSPORT; PRESCRIPTION; PREVALENCE; PRODUCTIVITY; RISK FACTOR; SOCIETY; UNITED STATES;

COSTS; HEROIN; OPIATE; OPIOID; OVERDOSE; POISONING;

ANALGESICS, OPIOID; HEALTH CARE COSTS; HUMANS; OPIOID-RELATED DISORDERS; PREVALENCE; UNITED STATES;

EID: 84885838006     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12183     Document Type: Article

References (41)

1. Wisniewski AM, Purdy CH, Blondell RD. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. J Addict Dis 2008;27:1-11.
2. Centers for Disease Control and Prevention (CDC). Vital signs: Overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60:1487-1492.
3. Centers for Disease Control and Prevention (CDC). Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:101-105.
4. Boyer EW. Management of opioid analgesic overdose. N Engl J Med 2012;367:146-155.
5. National Institute on Drug Abuse. Research Report Series: Prescription Drugs Abuse and Addiction. 2005. Available at: http://www.nida.nih.gov/PDF/RRPrescription.pdf (accessed 24 August 2011).
6. Katz NP, Adams EH, Chilcoat H, etal. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23:648-660.
7. Cepeda MS, Fife D, Chow W, Mastrogiovanni G, Henderson SC. Opioid shopping behavior: How often, how soon, which drugs, and what payment method. J Clin Pharmacol 2013;53:112-117.
8. Rigg KK, Kurtz SP, Surratt HL. Patterns of prescription medication diversion among drug dealers. Drugs (Abingdon Engl) 2012;19:144-155.
9. Resnik DB, Rehm M, Minard RB. The undertreatment of pain: Scientific, clinical, cultural, and philosophical factors. Med Health Care Philos 2001;4:277-288.
10. Alliance of States with Prescription Monitoring Programs. Status of States with PMPs. 2012. Available at: http://www.pmpalliance.org/pdf/pmp_status_table_2012.pdf (accessed 3 December 2012)
11. Albert S, Brason FW 2nd, Sanford CK, etal. Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Med 2011;12(suppl 2):S77-85.
12. White AG, Birnbaum HG, Mareva MN, etal. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-479.
13. Birnbaum HG, White AG, Reynolds JL, etal. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. Clin J Pain 2006;22:667-676.
14. Birnbaum HG, White AG, Schiller M, etal. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12:657-667.
15. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain 2011;27:194-202.
16. McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of opioid abuse and misuse determined from a Medicaid database. J Pain Palliat Care Pharmacother 2010;24:5-18.
17. Weisbrod B. The valuation of human capital. J Polit Econ 1961;69:425-436.
18. Bureau of Labor Statistics. Consumer Price Index. 2012.
19. Bureau of Labor Statistics. Employment Compensation Index. 2012.
20. Healthcare Cost and Utilization Project. HCUP Methods Series: The Cost of "Treat and Release" Visits to Hospital Emergency Departments. 2003 Report# 2007-05.
21. Schafer JL. Multiple imputation: A primer. Stat Methods Med Res 1999;8:3-15.
22. Centers for Medicare and Medicaid Services. 2009. National Payment Amounts. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/Downloads/PFALL09A.zip (accessed 5 January 2012).
23. United States Government Accountability Office. Ambulance Providers: Costs and Expected Medicaid Margins Vary Greatly. 2011. Available at: http://www.gao.gov/new.items/d07383.pdf (accessed 1 November 2011).
24. Thomson Reuters Micromedex Clinical Evidence Solutions. RED BOOK Drug References [Internet]. 2012.
25. BuyEMP. BuyEMP Product List. 2011. Available at: www.buyemp.com (accessed 2 December 2011).
26. Walsh DC, Connor E, Tracey LV, Goldberg GA. Egdahl RH. Posthospital convalescence and return to work. Health Aff (Millwood) 1989;8:76-90.
27. Grosse SD, Krueger KV, Mvundura M. Economic productivity by age and sex: 2007 estimates for the United States. Med Care 2009;47:S94-103.
28. U.S. Department of Justice National Drug Intelligence Center. The Economic Impact of Illicit Drug Use on American Society. 2011; 2011-Q0317-002. Available at: http://www.justice.gov/archive/ndic/pubs44/44731/44731p.pdf (accessed 24 June 2013).
29. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2009: Methodology Report. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
30. Larkin GL, Claassen CA, Pelletier AJ, Camargo CA Jr. National study of ambulance transports to United States emergency departments: Importance of mental health problems. Prehosp Disaster Med 2006;21:82-90.
31. Chen KW, Berger CC, Forde DP, etal. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011;11:90.
32. Hartzler B, Donovan DM, Huang Z. Comparison of opiate-primary treatment seekers with and without alcohol use disorder. J Subst Abuse Treat 2010;39:114-123.
33. Lewis ET, Combs A, Trafton JA. Reasons for under-use of prescribed opioid medications by patients in pain. Pain Med 2010;11:861-871.
34. Teitelbaum J, Rosenbaum S, Goplerud E. State laws permitting intoxication exclusions in insurance contracts: Implications for public health policy and practice. Public Health Rep 2004;119:585-587.
35. Kessler C, Chen J, Dill C, Tyndall G, Olszyk MD. State of affairs of emergency medicine in the Veterans Health Administration. Am J Emerg Med 2010;28:947-951.
36. Healthcare Cost and Utilization Project (HCUP). Introduction to the HCUP National Emergency Department Sample (NEDS), 2009. Available at: http://www.hcup-us.ahrq.gov/db/nation/neds/NEDS_Introduction_2009.jsp (accessed 11 December 2012).
37. Beletsky L, Ruthazer R, Macalino GE, etal. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: Challenges and opportunities. J Urban Health 2007;84:126-136.
38. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health 2011;88:1020-1030.
39. Enteen L, Bauer J, McLean R, etal. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010;87:931-941.
40. Piper TM, Stancliff S, Rudenstine S, etal. Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse 2008;43:858-870.
41. Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. Am J Public Health 2009;99:402-407.